When was ImmuNext founded?

ImmuNext was founded in 2009 and raised its 1st funding round 2 years after it was founded.

Where is ImmuNext located?

ImmuNext is headquartered in Lebanon, United States.

How many employees does ImmuNext have?

As of May 31, 2026, the latest employee count at ImmuNext is 3.

Is ImmuNext a funded company?

ImmuNext is a funded company, having raised an undisclosed amount across 11 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Aug 02, 2011.

When was the latest funding round of ImmuNext?

ImmuNext's latest funding was a $***** Grant (prize money) round on Jun 22, 2021, with participation from 1 investor. Its primary sector is Immunotherapy. In United States, the Immunotherapy sector has seen $1.14B in funding in 2026 to date.

Where does ImmuNext rank among its competitors?

ImmuNext ranks 1668th amongst 3287 active competitors, of which 1128 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of ImmuNext?

ImmuNext's top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Senti Bio. Among them, Immuneel secured the most recent funding round in June, 2026.

ImmuNext - 2026 Company Profile, Team, Funding & Competitors

Company Details

ImmuneNext is a Biotech company developing immune-based, protein-based therapeutics for immune-related disorders. Their lead program, Anti-VISTA, is a negative checkpoint regulator antagonist for the treatment of cancer. ImmuneNext partnered with Janssen Biotech in Sep 2012 (potential payment of upto USD 150 M) for the development of Anti-VISTA, which is currently in Phase I. In May 2016 ImmuNext received USD 1,800,000 Award for pre-clinical development of Anti-CD40L for Lupus and other autoimmune diseases.

Website: immunext.com
Email ID: *****@ImmuNext.com

Key Metrics

Founded Year

2009

Location

Lebanon, United States

Stage

Funding Raised

Latest Funding Round

Grant (prize money), Jun 22, 2021, $*****

Investors

NIH & 1 more

Ranked

1668^th among 3287 active competitors

Employee Count

3 as on May 31, 2026

Similar Companies

Jazz Pharmaceuticals & 3009 more

View ImmuNext's full profile

ImmuNext has raised funding over 11 rounds. Its first funding round was on Aug 02, 2011. Its latest funding round was a Grant (prize money) round on Jun 22, 2021 for $*****. 1 investor participated in its latest round. ImmuNext has 2 institutional investors.

Here is the list of recent funding rounds of ImmuNext:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 22, 2021	5962257	Grant (prize money)	9495615	8586724	4418121	9339213
Mar 01, 2018	3493823	Grant (prize money)	7573019	3353833	9702071	HHS
Aug 08, 2017	7236294	Grant (prize money)	5940923	3142696	4042648	HHS

Access funding benchmarks and valuations. Sign up today!

View details of ImmuNext's funding rounds and investors

The founders of ImmuNext is randolph noelle.

Here are the details of ImmuNext's key team members:

randolph noelle: Co-Founder & CSO of ImmuNext.
David DeLucia: CEO of ImmuNext.

View details of ImmuNext's Founder profiles and Board Members

ImmuNext's employee count trend

ImmuNext has 3 employees as of May 26. Here is ImmuNext's employee count trend over the years:

Uncover ImmuNext's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of ImmuNext include Jazz Pharmaceuticals, Sana Biotechnology and Senti Bio. Here is the list of Top 10 competitors of ImmuNext, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Google Ventures, Baillie Gifford & 17 others	75/100
3rd	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	72/100
5th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
6th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
7th	Karyopharm 2008, Newton (United States), Public	Biopharmaceutical company focused on developing and commercializing innovative cancer therapies	$98.4M	Foresite Capital, Avidity Partners & 16 others	71/100
8th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	71/100
9th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
10th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	True North, Khosla Ventures & 23 others	71/100
1668th	ImmuNext 2009, Lebanon (United States), Funding Raised	Biotech company developing immune-based, protein-based therapeutics for immune-related disorders	-	NIH, HHS	32/100